Studies that reported the usage of intravenous and/or oral ribavirin with or without immunomodulator(s)
| First author, year of publication, location of study . | Type of study . | No. of RSV cases . | LRI-final site of infection, no. (%) . | RSV deaths/LRI, no. (%) . | Treated at URI stage . | Progression, no. (%) . | Not treated at URI stage . | Progression, no. (%) . | Treated at LRI . | Deaths, no. (%) . | Not treated at LRI . | Deaths, no. (%) . | No. of patients on this regimen . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Khanna (2008), Switzerland4 * | Retrospective | 34 | 14 (41) | 6/14 (43) | 14 | 2 (14) | 8 | 0 | 14 | 6 (43) | 0 | 0 | 14 OR + IVIG + PVZ |
| Schleuning (2004), Germany60 | Retrospective | 8 | 4 (50) | 0 | 4 | 0 | 4 | 4 (100) | 4 | 2 (50) | 0 | 0 | 8 IR |
| Ljungman (2001), Sweden10 | Prospective | 46 | 27 (59) | 8/27 (30) | 0 | 0 | 10 | 0 | 6 | 2 (33) | 2 | 1 (50) | 6 IR |
| Sparrelid (1997), Sweden20 | Retrospective | 6 | 4 (67) | 2/4 (50) | 4 | 2 (50) | 2 | 2 (100) | 4 | 2 (50) | 0 | 0 | 6 IR-OR + 4 AR |
| Bowden (1997), WA56 | Retrospective | 88 | 35 (40) | 24/35 (69) | 0 | 0 | 0 | 0 | 10 | 6 (60) | 0 | 0 | 10 IR |
| Lewinsohn (1996), WA25 | Prospective | 28 | 12 (43) | 10/1 (83) | 0 | 0 | 28 | 12 (43) | 10 | 8 (80) | 2 | 2 (100) | 10 IR |
| Total | 210 | 96 (46) | 50/96 (52) | 22 | 4 (18) | 52 | 18 (35) | 48 | 26 (54) | 4 | 3 (75) | 0 |
| First author, year of publication, location of study . | Type of study . | No. of RSV cases . | LRI-final site of infection, no. (%) . | RSV deaths/LRI, no. (%) . | Treated at URI stage . | Progression, no. (%) . | Not treated at URI stage . | Progression, no. (%) . | Treated at LRI . | Deaths, no. (%) . | Not treated at LRI . | Deaths, no. (%) . | No. of patients on this regimen . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Khanna (2008), Switzerland4 * | Retrospective | 34 | 14 (41) | 6/14 (43) | 14 | 2 (14) | 8 | 0 | 14 | 6 (43) | 0 | 0 | 14 OR + IVIG + PVZ |
| Schleuning (2004), Germany60 | Retrospective | 8 | 4 (50) | 0 | 4 | 0 | 4 | 4 (100) | 4 | 2 (50) | 0 | 0 | 8 IR |
| Ljungman (2001), Sweden10 | Prospective | 46 | 27 (59) | 8/27 (30) | 0 | 0 | 10 | 0 | 6 | 2 (33) | 2 | 1 (50) | 6 IR |
| Sparrelid (1997), Sweden20 | Retrospective | 6 | 4 (67) | 2/4 (50) | 4 | 2 (50) | 2 | 2 (100) | 4 | 2 (50) | 0 | 0 | 6 IR-OR + 4 AR |
| Bowden (1997), WA56 | Retrospective | 88 | 35 (40) | 24/35 (69) | 0 | 0 | 0 | 0 | 10 | 6 (60) | 0 | 0 | 10 IR |
| Lewinsohn (1996), WA25 | Prospective | 28 | 12 (43) | 10/1 (83) | 0 | 0 | 28 | 12 (43) | 10 | 8 (80) | 2 | 2 (100) | 10 IR |
| Total | 210 | 96 (46) | 50/96 (52) | 22 | 4 (18) | 52 | 18 (35) | 48 | 26 (54) | 4 | 3 (75) | 0 |
NA indicates not available.
Including 7 patients with leukemia.